Cytosolic Phospholipase A2 Alpha Regulates TLR Signaling and Migration in Metastatic 4T1 Cells

Published on 2019in International Journal of Molecular Sciences4.18
· DOI :10.3390/ijms20194800
Hanna Maja Tunset2
Estimated H-index: 2
Astrid Jullumstrø Feuerherm8
Estimated H-index: 8
+ 2 AuthorsSiver Andreas Moestue13
Estimated H-index: 13
Metastatic disease is the leading cause of death in breast cancer patients. Disrupting the cancer cell’s ability to migrate may be a strategy for hindering metastasis. Cytosolic phospholipase A2 α (cPLA2α), along with downstream proinflammatory and promigratory metabolites, has been implicated in several aspects of tumorigenesis, as well as metastasis, in various types of cancer. In this study, we aim to characterize the response to reduced cPLA2α activity in metastatic versus non-metastatic cells. We employ an isogenic murine cell line pair displaying metastatic (4T1) and non-metastatic (67NR) phenotype to investigate the role of cPLA2α on migration. Furthermore, we elucidate the effect of reduced cPLA2α activity on global gene expression in the metastatic cell line. Enzyme inhibition is achieved by using a competitive pharmacological inhibitor, cPLA2α inhibitor X (CIX). Our data show that 4T1 expresses significantly higher cPLA2α levels as compared to 67NR, and the two cell lines show different sensitivity to the CIX treatment with regards to metabolism and proliferation. Inhibition of cPLA2α at nontoxic concentrations attenuates migration of highly metastatic 4T1 cells, but not non-metastatic 67NR cells. Gene expression analysis indicates that processes such as interferon type I (IFN-I) signaling and cell cycle regulation are key processes regulated by cPLA2a in metastatic 4T1 cells, supporting the findings from the biological assays. This study demonstrates that two isogenic cancer cell lines with different metastatic potential respond differently to reduced cPLA2α activity. In conclusion, we argue that cPLA2α is a potential therapeutic target in cancer and that enzyme inhibition may inhibit metastasis through an anti-migratory mechanism, possibly involving Toll-like receptor signaling and type I interferons.
  • References (59)
  • Citations (0)
#1Astrid Jullumstrø Feuerherm (NTNU: Norwegian University of Science and Technology)H-Index: 8
#2Edward A. Dennis (UCSD: University of California, San Diego)H-Index: 80
Last.Bent Johansen (NTNU: Norwegian University of Science and Technology)H-Index: 22
view all 3 authors...
#1Chaelin Lee (Sejong University)
#2Hien Thi Thu Do (Sejong University)H-Index: 1
Last.Inmoo Rhee (Sejong University)H-Index: 1
view all 6 authors...
#1Kunlin Wu (Fujian Medical University)H-Index: 3
#2Huihao Zhang (Fujian Medical University)H-Index: 3
Last.Xiangjin Chen (Fujian Medical University)H-Index: 4
view all 9 authors...
#1Hui Fu (Tianjin University of Traditional Chinese Medicine)H-Index: 4
#2Yuchao He (TMUCIH: Tianjin Medical University Cancer Institute and Hospital)H-Index: 3
Last.Hua Guo (TMUCIH: Tianjin Medical University Cancer Institute and Hospital)H-Index: 5
view all 9 authors...
#1Laura M. Snell (UHN: University Health Network)H-Index: 6
#2Tracy L. McGaha (U of T: University of Toronto)H-Index: 26
Last.David G. Brooks (U of T: University of Toronto)H-Index: 6
view all 3 authors...
Cited By0
View next paperCytosolic phospholipase A2 activation correlates with HER2 overexpression and mediates estrogen-dependent breast cancer cell growth.